DuPont/Mallinckrodt patent suit
Mallinckrodt will continue to market pyrophosphate radiopharmaceutical products following the settlement of a patent infringement suit with DuPont. Earlier, a U.S. district court ruled in favor of DuPont, which in 1984 filed an infringement action relating to three DuPont patents covering certain pyrophosphate radiopharmaceuticals. Under the settlement, announced Jan. 18, DuPont will be compensated for past infringement and will receive royalties from Mallinckrodt.
You may also be interested in...
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.
FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.